Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 973 across all filing types
Latest filing 2017-09-14 Director's Dealing
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Biotec Pharmacon - Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled 'Mandatory notification of trade' and explicitly states that the CEO, Svein Lien, purchased shares in the company. This action constitutes a personal share transaction by a company director/executive (insider trade). This directly matches the definition for Director's Dealing (DIRS). The document length is very short (774 chars), but the content is a direct notification of a trade, not an announcement about a report, making DIRS the most specific fit over the general RNS.
2017-09-14 English
Biotec Pharmacon appoints new CEO
Board/Management Information Classification · 99% confidence The document is a press release announcing a significant change in senior leadership: the hiring of a new CEO (Christian Jørgensen) and the resignation of the previous CEO (Svein Lien). This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2017-09-12 English
Biotec Pharmacon appoints new CEO
Board/Management Information Classification · 100% confidence The document is a short announcement titled "Biotec Pharmacon appoints new CEO". It explicitly states the hiring of a new CEO, Christian Jørgensen, and the resignation of the previous CEO, Svein Lien, effective October 2, 2017. This content directly relates to changes in senior management personnel. Based on the provided definitions, this aligns perfectly with the Board/Management Information category (MANG). The document length is short (2209 chars), but it is the primary announcement itself, not an announcement *about* a report, so RPA/RNS is not the primary classification.
2017-09-12 English
Woulgan® application to be reconsidered by UK Drug Tariff
Regulatory Filings Classification · 95% confidence The document is a press release dated September 12, 2017, announcing positive feedback regarding an appeal for reimbursement of a product (Woulgan) by a UK drug tariff panel. It discusses regulatory feedback, clinical studies, market strategy, and provides contact information. This type of announcement, detailing a specific regulatory or legal development concerning the company's operations or product status, fits best under 'Legal Proceedings Report' (LTR) if it relates to a dispute or regulatory challenge, or potentially 'Regulatory Filings' (RNS) as a general update. Since it specifically concerns a regulatory appeal process and feedback on a product's status with a tariff body, it is a specific regulatory/legal update. Given the options, 'LTR' (Legal Proceedings Report) is the closest fit for reporting on a dispute/appeal process with a regulatory body, although 'RNS' (Regulatory Filings) is a strong fallback. Given the context of an 'appeal panel' and the nature of the dispute over evidence recognition, LTR is chosen over the general RNS.
2017-09-12 English
Woulgan® application to be reconsidered by UK Drug Tariff
Legal Proceedings Report Classification · 99% confidence The document is a short press release dated September 12, 2017, announcing that the UK Drug Tariff appeal panel will reconsider Biotec Pharmacon's application for reimbursement of their product, Woulgan®. It discusses regulatory feedback, strategy, and market positioning, but it is not a full financial report (like 10-K or IR), a transcript (CT), or a formal dividend/share change notice. It is a specific announcement regarding a regulatory/market access decision concerning a product. This type of specific, non-financial regulatory update that doesn't fit into the other specific categories (like LTR for legal proceedings or DIV for dividends) is best classified as a general Regulatory Filing (RNS), as it is an announcement of an event impacting the company's operations/market access.
2017-09-12 English
Biotec Pharmacon - resignation of board member
Board/Management Information Classification · 98% confidence The document text explicitly states the 'resignation of board member Jan Raa' from the Board of Directors of Biotec Pharmacon ASA. This directly relates to changes in the company's board of directors or senior management. According to the definitions, this corresponds to the Board/Management Information category.
2017-09-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.